Gliknik Inc.

Quick facts

Phase 2 pipeline

• GL-0817 · Oncology
  GL-0817 is an anti-CD47 monoclonal antibody.

Phase 1 pipeline

• GL-0719

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Gliknik Inc. portfolio CI brief
• Gliknik Inc. pipeline updates RSS